Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

- Huntington's Disease
- Completed

Study Title: A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease

Teva Identifier: ACR16 C008

ClinicalTrials.gov Identifier: NCT00665223

Study Status: Completed

Trial Condition(s): Huntington's Disease

Interventions: Drug: ACR16 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 30 Years and older

Trial Duration: 04/01/2008 - 06/01/2011

Phase: Phase 3

Study Type

Interventional